GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious Puberty

Time

2026-06-24

Readership

Recently, GenSci's Triptorelin Acetate for Injection (II) has been officially granted marketing approval from NMPA. It is indicated for the treatment of central precocious puberty (CPP) in children weighing 20 kg or more.

Central precocious puberty (CPP) is a disorder caused by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. This early activation raises gonadotropin-releasing hormone (GnRH) levels, drives gonadal development and triggers sex hormone secretion. CPP can impair children's growth potential and affect their psychological well-being, and its incidence rate in China has been increasing year by year^[1].

Gonadotropin-releasing hormone agonists (GnRHa) are recommended by clinical guidelines and consensus statements globally. GenSci's Triptorelin Acetate for Injection (II) has demonstrated its efficacy and safety in a multi-center, open-label, single-arm clinical trial for pediatric CPP.

Triptorelin Acetate for Injection (II) marks another key milestone in GenSci's pediatric health portfolio. Moving forward, GenSci will continue to advance the marketing, manufacturing and commercialization of the product, drive its broad clinical adoption, and better serve pediatric patients and their families.

Disclosure Notice:

1. This press release is provided as a medical information source for healthcare experts only and is not used for commercial purposes.

2. For diagnosis and treatment information regarding specific medical conditions, please follow the advice and guidance of qualified healthcare professionals.

Reference:

[1] The Subspecialty Group of Endocrinology, Heredity and Metabolism, Society of Pediatrics, Chinese Medical Association; Editorial Board of Chinese Journal of Pediatrics. (2023). Expert consensus on the diagnosis and treatment of central precocious puberty (2022) [Consensus statement]. Chinese Journal of Pediatrics, 61(1), 16–22.